Talking It Out: Perseverance Helps Sponsors Overcome Disagreements With FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Some of the most valuable lessons learned out of Pharmaceutical Approvals Monthly’s Drug Review Profile series involve getting FDA to be flexible about what kind of clinical data it requires.
You may also be interested in...
Reader, Be Wary: Sponsors Keep Most 'Complete Response' Letter Content Under Wraps, FDA Says
Agency analysis provides rare portrait of 'complete response' letters while adding to the case for increased transparency.
Beyond "Breakthrough": FDA, Industry See Benefits For Drugs Outside Expedited Pathway
Pharmaceutical manufacturers and FDA have enthusiastically embraced the “breakthrough therapy” program as a way to more quickly bring new drugs with substantial effects to patients in need. With two years of program experience now under their belts, agency and industry representatives talk about learnings and best practices that could be applied to the development and review of drugs outside the program.
FDAAA Fading? REMS Use Continues To Decline As Drug Safety Law Matures
FDA’s use of REMS continues to fall to almost undetectable levels, with the agency using the safety tools just a handful of times in the sixth full year of the program. REMS are now very much the exception and not the rule for new products – but still a very important exception.